Table 1 Patient characteristics and perioperative data
Gender male/female ratio n (%) | 23/8 (74/26) |
Age (years) mean ± SD | 65 ± 8 |
Arterial hypertension n (%) | 23 (74) |
Chronic obstructive lung disease n (%) | 4 (12) |
Diabetes n (%) | 5 (16) |
Current smoker n (%) | 10 (32) |
Left ventricular ejection fraction n (%) | |
 > 50% | 21 (67) |
 40–50% | 4 (12) |
 < 40% | 7 (22) |
Height (cm) mean ± SD | 172 ± 9 |
Bodyweight (kg) mean ± SD | 82 ± 16 |
Body mass index (kg/m2) mean ± SD | 28 ± 5 |
No antiplatelet therapy n (%) | 16 (51) |
Single antiplatelet therapy n (%) | 11 (35) |
Dual antiplatelet therapy n (%) | 5 (16) |
Surgical procedure n (%) | |
 CABG only | 10 (32) |
 CABG with aortic valve replacement/repair | 7 (22) |
 CABG with mitral valve replacement/repair | 7 (22) |
 Aortic valve replacement | 7 (22) |
Vasoactive agents | |
 Dobutamine n (%) | 11 (35) |
 Noradrenaline n (%) | 31 (100) |
 Levosimendan n (%) | 5 (16) |
Blood and coagulation products | |
 Packed red blood cells n (%) | 13 (41) |
 Fibrinogen n (%) | 11 (35) |
 Tranexamic acid n (%) | 31 (100) |
 Tranexamic acid (g) mean ± SD | 2.5 ± 1.0 |
 Cardiopulmonary bypass time (min) mean ± SD | 148 ± 75 |
 Aortic cross-clamping time (min) mean ± SD | 93 ± 48 |
 Mild hypothermia n (%) | 9 (29) |
 Highest serum lactate level (mg/dL) mean ± SD | 2.7 ± 2 |